Lupus Nephritis and Kidney Involvement

Table of Contents

  1. What Lupus Nephritis Is
  2. Why the Kidney Biopsy Is the Whole Game
  3. The ISN/RPS 2003 Classification (Class I–VI)
  4. Activity vs Chronicity Indices
  5. When to Biopsy — The Triggering Numbers
  6. Induction Therapy: MMF vs Cyclophosphamide
  7. Steroids — High-Dose vs Moderate
  8. Belimumab Add-On (BLISS-LN)
  9. Voclosporin (AURA-LV and AURORA)
  10. Rituximab in Refractory Disease
  11. Maintenance Therapy — The Long Haul
  12. Dialysis and Transplant Outcomes
  13. Pregnancy With Lupus Nephritis
  14. Day-to-Day Self-Care
  15. Key Research Papers
  16. Research Papers
  17. Connections

What Lupus Nephritis Is

Lupus nephritis is what happens when systemic lupus erythematosus (SLE) attacks the glomeruli — the million tiny filters in each kidney that clean your blood. Immune complexes (antibody clumps, mostly containing anti-dsDNA) deposit in the glomerular basement membrane and mesangium. The body treats those deposits as wounds and pours in complement, neutrophils, and cytokines. The filters scar. Protein leaks into the urine. Waste products build up in the blood.

Roughly 35–60% of lupus patients develop clinically significant kidney involvement at some point, with higher rates in Black, Hispanic, and Asian patients than in white patients. Most cases appear in the first five years after SLE diagnosis — often in the first year — but new nephritis can show up a decade later, which is why every lupus follow-up visit includes a urine check.

Early lupus nephritis is usually silent. You will not feel your kidneys failing. The first sign is almost always a laboratory abnormality: protein in the urine, blood in the urine, a rising creatinine, or edema around the ankles or eyelids. By the time symptoms are obvious — fatigue, shortness of breath, uncontrolled blood pressure, foamy urine — damage may already be substantial. That is the single most important thing to know: lupus nephritis is diagnosed from labs, not from how you feel.

Why the Kidney Biopsy Is the Whole Game

Every serious decision in lupus nephritis — whether to use cyclophosphamide or mycophenolate, how long to treat, what prognosis to quote — depends on the kidney biopsy. Two patients with identical proteinuria and identical creatinine can have completely different biopsies and need completely different regimens. You cannot skip this step, and no blood test substitutes for it.

The procedure is outpatient. An interventional radiologist or nephrologist uses ultrasound guidance to pass a thin needle through the back and take two or three cores of kidney tissue. It takes about 30 minutes; you lie flat for four to six hours afterward to minimize bleeding. Major complications (significant bleeding, need for transfusion) occur in roughly 1–2% of biopsies. You go home the same day in most centers.

The pathologist then classifies the biopsy according to the ISN/RPS 2003 system (International Society of Nephrology / Renal Pathology Society), grading both what class of nephritis you have and how active and how scarred the tissue is. Those two findings determine everything that follows.

The ISN/RPS 2003 Classification (Class I–VI)

Six classes, each with a distinct prognosis and treatment path:

Class I — Minimal mesangial lupus nephritis. Immune deposits visible only by immunofluorescence or electron microscopy. Normal light microscopy. Usually no proteinuria, no hematuria. Excellent prognosis. No lupus-specific kidney treatment needed — manage systemic lupus as usual.

Class II — Mesangial proliferative lupus nephritis. Mesangial hypercellularity plus deposits on light microscopy. Mild proteinuria (usually under 1 g/day) and microscopic hematuria. Good prognosis. Again, no specific nephritis regimen — hydroxychloroquine, ACE inhibitor or ARB for blood-pressure and proteinuria control, and standard SLE therapy.

Class III — Focal lupus nephritis. Active or inactive endocapillary or extracapillary glomerulonephritis involving less than 50% of glomeruli. Proteinuria (often nephrotic), hematuria, sometimes an active urinary sediment with red-cell casts, rising creatinine. This is the first class that demands aggressive immunosuppression. Subdivided into III (A) active, III (A/C) active and chronic, and III (C) chronic sclerosing lesions only.

Class IV — Diffuse lupus nephritis. The same proliferative disease as Class III but involving 50% or more of glomeruli. The most common and the most dangerous class. Heavy proteinuria, red-cell casts, rising creatinine, often hypertension and edema. Untreated or undertreated Class IV progresses to end-stage kidney disease in the majority of patients. With modern induction therapy, ten-year renal survival is now around 80–90%. Further subdivided into IV-S (segmental, lesions affecting part of each involved glomerulus) and IV-G (global, lesions affecting the whole glomerulus).

Class V — Membranous lupus nephritis. Subepithelial immune deposits thicken the glomerular basement membrane. Nephrotic-range proteinuria (often >3.5 g/day), edema, hypoalbuminemia, hyperlipidemia — the nephrotic syndrome. Creatinine typically stays normal for years. Pure Class V has a more indolent course than proliferative disease but raises thrombosis risk and causes protein wasting. Class V often coexists with III or IV (reported as "III + V" or "IV + V"), and when it does, the proliferative component dictates treatment.

Class VI — Advanced sclerosing lupus nephritis. More than 90% of glomeruli globally sclerosed. This is burnt-out disease. Immunosuppression no longer helps the kidneys — it only exposes you to infection risk. The focus shifts to dialysis planning, transplant workup, and controlling lupus activity elsewhere in the body.

Activity vs Chronicity Indices

Classification alone is not enough. The pathologist also scores two indices that tell you how reversible the damage is:

Activity index (0–24). Scores features that respond to immunosuppression: endocapillary hypercellularity, karyorrhexis/fibrinoid necrosis, cellular crescents, subendothelial hyaline deposits (wire loops), interstitial inflammation. A high activity index means "there is inflammation left to quench" — worth treating hard.

Chronicity index (0–12). Scores irreversible damage: glomerular sclerosis, fibrous crescents, tubular atrophy, interstitial fibrosis. A high chronicity index means "much of what is left is scar, not fire." Treatment is less helpful, toxicity risk weighs more, and prognosis is guarded regardless of therapy.

Two Class IV biopsies tell very different stories: Class IV with activity 15, chronicity 2 is the patient you throw the kitchen sink at — this kidney will likely recover. Class IV with activity 4, chronicity 10 is a patient in whom aggressive therapy may do more harm than good. Ask your nephrologist for both numbers when you review the biopsy report.

When to Biopsy — The Triggering Numbers

Any of the following in a lupus patient is a standard indication to biopsy:

The 2019 EULAR/ERA-EDTA and 2024 KDIGO recommendations all agree: you cannot treat lupus nephritis blind. Even if you are certain clinically, the class and the chronicity index will shape how you treat and how long you treat. The only reasons to defer biopsy are absolute contraindications — uncontrolled bleeding risk, uncontrollable blood pressure, a single functioning kidney in certain situations, or pregnancy beyond the second trimester — and those are negotiable with an experienced operator.

Induction Therapy: MMF vs Cyclophosphamide

Induction means "quench the fire" — get the active inflammation under control in the first 3–6 months. Two first-line regimens have dominated the evidence for twenty years:

Mycophenolate mofetil (MMF). Oral tablet, dosed 2–3 grams per day in divided doses. The Aspreva Lupus Management Study (ALMS) and earlier trials showed MMF is at least as effective as IV cyclophosphamide for induction, with a cleaner side-effect profile — no bladder toxicity, less ovarian suppression, less hair loss. MMF has become the default induction drug for most Class III and Class IV patients, especially women of childbearing age and patients of African or Hispanic ancestry, where MMF may actually outperform cyclophosphamide.

IV cyclophosphamide — Euro-Lupus regimen. The landmark Euro-Lupus Nephritis Trial (Houssiau et al., 2002) showed that low-dose IV cyclophosphamide 500 mg every two weeks for six doses (total 3 grams) worked as well as the older, much more toxic NIH regimen of monthly high-dose pulses for six months followed by quarterly pulses. Ten-year follow-up confirmed durable benefit. Euro-Lupus is the default cyclophosphamide regimen in European populations today, with MMF preferred for non-European ancestries.

Practical comparison your rheumatologist is thinking about:

Steroids — High-Dose vs Moderate

For decades, induction started with three days of IV methylprednisolone pulses (500–1000 mg daily) followed by oral prednisone 1 mg/kg/day — often 60 mg or more — tapered slowly over a year. The toll was catastrophic: weight gain, diabetes, cataracts, osteoporosis, avascular necrosis of the hips, cushingoid features, mood changes, infection.

The Lupus Nephritis Trial (Rovin et al.) and subsequent real-world studies have changed practice. Current recommendations (EULAR 2023, KDIGO 2024) favor:

The data behind this shift are consistent: lower steroid doses combined with modern steroid-sparing immunosuppression achieve the same renal response rates as the old high-dose regimens with fewer infections and far less long-term damage. If your nephrologist is still quoting 1 mg/kg/day as a starting dose, ask directly whether a lower dose with a belimumab or voclosporin add-on would be appropriate for your biopsy.

Belimumab Add-On (BLISS-LN)

Belimumab is a monoclonal antibody against BLyS (B-lymphocyte stimulator). By depriving autoreactive B cells of a key survival signal, it reduces autoantibody production. It was first approved for non-renal lupus in 2011.

The BLISS-LN trial (Furie et al., NEJM 2020) randomized 448 patients with active Class III, IV, or V lupus nephritis to receive either standard induction (MMF or cyclophosphamide plus steroids) alone or the same regimen plus IV belimumab 10 mg/kg monthly. At two years, 43% of belimumab patients achieved the primary efficacy renal response vs 32% on standard therapy alone, and the risk of renal events or death was significantly lower. The FDA approved belimumab for lupus nephritis in December 2020.

In practice, belimumab is now added to induction and continued through maintenance for most Class III, IV, and V patients who can tolerate it and whose insurance will cover it. It is given IV monthly or as a weekly subcutaneous injection (200 mg). Infection risk is modestly increased, and depression has been reported; serious adverse events are uncommon.

Voclosporin (AURA-LV and AURORA)

Voclosporin is a next-generation calcineurin inhibitor, structurally related to cyclosporine but with more predictable pharmacokinetics (no trough monitoring needed) and a better metabolic profile. It reduces proteinuria both by immunosuppression and by a direct effect on the podocyte cytoskeleton that stabilizes the glomerular filtration barrier.

Two trials drove approval. AURA-LV (phase 2) showed that adding voclosporin 23.7 mg twice daily to MMF plus low-dose steroids roughly doubled the complete renal response rate at 24 weeks. AURORA-1 (phase 3, Rovin et al., Lancet 2021) confirmed the benefit: 41% complete renal response at one year with voclosporin vs 23% with MMF plus steroids alone, with proteinuria dropping faster in the voclosporin arm. AURORA-2 (two-year extension) showed the benefit was durable without a decline in GFR.

FDA approved voclosporin for adult lupus nephritis in January 2021. It is oral, taken twice daily, and does not require drug-level monitoring. Side effects include a small reversible decrease in eGFR early on (reflecting intrarenal hemodynamics, not true damage), hypertension, and occasional hyperkalemia. Voclosporin and belimumab are now the two main "add-on" pillars alongside MMF or cyclophosphamide; which you get often depends on insurance formulary and clinician preference rather than head-to-head evidence, since they have not been directly compared.

Rituximab in Refractory Disease

Rituximab depletes CD20+ B cells. The LUNAR trial did not meet its primary endpoint for lupus nephritis — meaning rituximab is not first-line. But for patients who fail standard induction (persistent heavy proteinuria or worsening creatinine despite MMF or cyclophosphamide plus steroids plus a belimumab or voclosporin add-on), rituximab is a widely used off-label rescue option with reasonable real-world evidence of benefit. Typical dosing: 1 gram IV at day 0 and day 14, sometimes repeated at six months.

Rituximab's main risks are infections (especially if repeated) and hypogammaglobulinemia with chronic use. Check IgG levels annually if you are on long-term B-cell depletion. Your covering rheumatologist will also add Pneumocystis jirovecii prophylaxis (typically trimethoprim-sulfamethoxazole) during periods of intensive immunosuppression.

For a deeper look at all three biologic options, see the biologics page.

Maintenance Therapy — The Long Haul

Once induction has quieted the inflammation (proteinuria falling toward 500 mg/g, creatinine stable, inactive sediment), treatment shifts to maintenance — lower-intensity therapy to prevent relapse. Lupus nephritis relapses in roughly 30–40% of patients, and each relapse adds scar. Maintenance is not optional.

Typical maintenance regimen:

Maintenance duration is at least 3–5 years after complete renal response. Some patients stay on low-dose maintenance indefinitely; others taper off with close monitoring. Stopping too soon predicts relapse. Your nephrologist and rheumatologist will watch urine protein, sediment, creatinine, complement (C3, C4), and anti-dsDNA every 1–3 months through induction and every 3–6 months in maintenance.

Dialysis and Transplant Outcomes

Despite modern therapy, roughly 10–20% of lupus nephritis patients progress to end-stage kidney disease within ten years, with higher rates in Black and Hispanic patients and in those whose disease was caught late. If your kidney function declines toward end-stage, the news is better than it used to be:

For the broader picture of what kidney disease means day-to-day — dialysis choices, transplant workup, diet — see kidney disease.

Pregnancy With Lupus Nephritis

Pregnancy and lupus nephritis need careful choreography. The rules:

See the pregnancy and lupus page for the full medication swap list, antiphospholipid considerations, and neonatal lupus screening.

Day-to-Day Self-Care

Medication is most of the battle, but a handful of daily habits genuinely move the needle:

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on lupus nephritis classification, therapy, and outcomes:

  1. Lupus nephritis ISN/RPS classification
  2. MMF vs cyclophosphamide induction for lupus nephritis
  3. Euro-Lupus Nephritis Trial long-term outcomes
  4. Belimumab in lupus nephritis (BLISS-LN)
  5. Voclosporin AURORA trials in lupus nephritis
  6. Rituximab in refractory lupus nephritis
  7. Kidney transplant outcomes in lupus nephritis
  8. Pregnancy outcomes in lupus nephritis
  9. Activity and chronicity indices in lupus nephritis
  10. SGLT2 inhibitors in proteinuric kidney disease

Connections

Back to Table of Contents